In the title centrosymmetric dinuclear nickel complex, [Ni(2)(C(22)H(30)N(4)O(2))(NO(3))(2)], each of the two Ni(II) atoms has a distorted octa-hedral geometry, defined by two N atoms and two O atoms from the macrocyclic ligand and two O atoms from a chelating nitrate anion. The two Ni atoms are bridged by two phenolate O atoms, forming a four-membered Ni(2)O(2) ring.

Several derivatives of 5-O-mycaminosyltylonolide substituted at C-23 have been prepared; these are 23-deoxy-23-C-methylene (3), 23-deoxy-23-C-(methoxycarbonylmethylene) (5), 23-deoxy-23-C-(ethoxycarbonylmethylene) (7), and 23-deoxy-23-C-(butoxycarbonylmethylene) (9), 23-deoxy-23-C-[(2E)-3-(ethoxycarbonyl)-2-propenylene] (11), and 23-deoxy-23-(dimethylaminoimino) (13), and 14-de(hydroxymethyl)-1...

In the centrosymmetric and dinuclear title complex, [Mn(2)(C(22)H(22)N(4)O(2))(ClO(4))(2)], the two Mn atoms are bridged by two phenolate O atoms of the N(4)O(2) macrocycle with an Mn⋯Mn distance of 2.9228 (11) Å. The distorted square-pyramidal N(2)O(3) coordination geometry is completed by an O atom derived from a perchlorate anion.

In just 10 years from its discovery in 2000, interleukin-23 has quickly moved from being recognized as a pro-inflammatory cytokine to a key player and potential therapeutic target in psoriasis.

The recent advances in the understanding of psoriasis pathogenesis have clarified the pivotal role of interleukin (IL)-23. It is a heterodimeric cytokine consisting of two subunits, the unique p19 and the p40, which are shared with IL-12. The basic role of IL-23 in psoriasis is the activation and maintenance of the T-helper 17 pathway. New research findings indicate that IL-23 is more important...